Hypertension Experts Push For New Trial Of Renal Denervation To Show Efficacy
This article was originally published in The Gray Sheet
Since Medtronic’s sham-controlled SYMPLICITY HTN-3 trial of its Symplicity renal denervation device failed to meet its primary efficacy endpoint, manufacturers developing renal denervation systems have been working with researchers and FDA to map the next steps in researching and developing this hypertension therapy.
You may also be interested in...
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.
FDA is looking forward to reviewing PMAs from several anti-hypertension devices in the coming years – including technologies from Medtronic, ReCor Medical, ROX Medical, and Vascular Dynamics – so the agency convened its Circulatory System Devices Panel on Dec. 5 to get recommendation on pre-market clinical trial design, post-approval study design, indications and labeling for such devices.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.